Literature DB >> 33691596

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo.

Simone Mester1,2, Mitchell Evers3, Saskia Meyer4, Jeannette Nilsen1,2, Victor Greiff1, Inger Sandlie1,5, Jeanette Leusen3, Jan Terje Andersen1,2.   

Abstract

Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere with pH-dependent binding of albumin to the human neonatal Fc receptor (FcRn), as FcRn acts as the principal regulator of the half-life of albumin. Thus, there is a need to know how ABDs act in the context of fusion partners and human FcRn. Here, we studied the binding and transport properties of human immunoglobulin A1 (IgA1), fused to a Streptococcus protein G-derived engineered ABD, in in vitro and in vivo systems harboring human FcRn. IgA has great potential as a therapeutic protein, but its short half-life is a major drawback. We demonstrate that ABD-fused IgA1 binds human FcRn pH-dependently and is rescued from cellular degradation in a receptor-specific manner in the presence of albumin. This occurs when ABD is fused to either the light or the heavy chain. In human FcRn transgenic mice, IgA1-ABD in complex with human albumin, gave 4-6-fold extended half-life compared to unmodified IgA1, where the light chain fusion showed the longest half-life. When the heavy chain-fused protein was pre-incubated with an engineered human albumin with improved FcRn binding, cellular rescue and half-life was further enhanced. Our study reveals how an ABD, which does not interfere with albumin binding to human FcRn, may be used to extend the half-life of IgA.Abbreviations: ABD - Albumin binding domain, ADA - anti-drug-antibodies, ADCC - Antibody-dependent cellular cytotoxicity, ELISA - Enzyme-linked Immunosorbent assay, FcαRI - Fcα receptor, FcγR - Fcγ receptor, FcRn - The neonatal Fc receptor, GST - Glutathione S-transferase, HC - Heavy chain, HERA - Human endothelial cell-based recycling assay, Her2 - Human epidermal growth factor 2, HMEC - Human microvascular endothelial cells, IgG - Immunoglobulin G, IgA - Immunoglobulin A, LC - Light chain, QMP - E505Q/T527M/K573P, WT - Wild type.

Entities:  

Keywords:  Immunoglobulin A (IgA); albumin-binding-domain (ABD); half-life; human FcRn transgenic mice; human serum albumin (HSA); the neonatal Fc receptor (FcRn)

Year:  2021        PMID: 33691596      PMCID: PMC7954421          DOI: 10.1080/19420862.2021.1893888

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  71 in total

1.  Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).

Authors:  A P West; P J Bjorkman
Journal:  Biochemistry       Date:  2000-08-15       Impact factor: 3.162

2.  Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.

Authors:  Raimund J Ober; Cruz Martinez; Carlos Vaccaro; Jinchun Zhou; E Sally Ward
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

3.  Streptococcal protein G, expressed by streptococci or by Escherichia coli, has separate binding sites for human albumin and IgG.

Authors:  L Björck; W Kastern; G Lindahl; K Widebäck
Journal:  Mol Immunol       Date:  1987-10       Impact factor: 4.407

Review 4.  The use of gene fusions to protein A and protein G in immunology and biotechnology.

Authors:  S Ståhl; P A Nygren
Journal:  Pathol Biol (Paris)       Date:  1997-01

5.  Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

Authors:  Jan Terje Andersen; Jason Cameron; Andrew Plumridge; Leslie Evans; Darrell Sleep; Inger Sandlie
Journal:  J Biol Chem       Date:  2013-07-01       Impact factor: 5.157

Review 6.  Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).

Authors:  Elena Santagostino
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

7.  NetMHCpan, a method for MHC class I binding prediction beyond humans.

Authors:  Ilka Hoof; Bjoern Peters; John Sidney; Lasse Eggers Pedersen; Alessandro Sette; Ole Lund; Søren Buus; Morten Nielsen
Journal:  Immunogenetics       Date:  2008-11-12       Impact factor: 2.846

8.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

Review 9.  The albumin-binding domain as a scaffold for protein engineering.

Authors:  Johan Nilvebrant; Sophia Hober
Journal:  Comput Struct Biotechnol J       Date:  2013-09-01       Impact factor: 7.271

10.  IgA EGFR antibodies mediate tumour killing in vivo.

Authors:  Peter Boross; Stefan Lohse; Maaike Nederend; Johannes Hendrik Marco Jansen; Geert van Tetering; Michael Dechant; Matthias Peipp; Louise Royle; Li Phing Liew; Louis Boon; Nico van Rooijen; Wim K Bleeker; Paul W H I Parren; Jan G J van de Winkel; Thomas Valerius; Jeanette H W Leusen
Journal:  EMBO Mol Med       Date:  2013-08       Impact factor: 12.137

View more
  4 in total

1.  Rabbit IgA Hinges That Resist IgA1 Protease Action Provide Options for Improved IgA-Based Therapeutic Agents.

Authors:  Patrícia de Sousa-Pereira; Dennis K Lanning; Pedro J Esteves; Christian Spoerry; Jenny M Woof; Ana Pinheiro
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

2.  Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma.

Authors:  Marjolein Stip; Kaylee Keller; Hanneke Willemen; Niels Eijkelkamp; Jeanette Leusen; Mitchell Evers; Maaike Nederend; Marco Jansen; Chilam Chan; Kevin Budding; Stefan Nierkens; Thomas Valerius; Friederike Meyer-Wentrup
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

Review 3.  Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications.

Authors:  Bruce A Molitoris; Ruben M Sandoval; Shiv Pratap S Yadav; Mark C Wagner
Journal:  Physiol Rev       Date:  2022-04-04       Impact factor: 46.500

Review 4.  Application of Elastin-like Polypeptide in Tumor Therapy.

Authors:  Xianggang Shi; Dongfeng Chen; Guodong Liu; Hailing Zhang; Xiaoyan Wang; Zhi Wu; Yan Wu; Feng Yu; Qinggang Xu
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.